Hidden Dangers: A Cryptic Exon Disrupts BRCA2 mRNA

James D. Fackenthal1, Younghee Lee2, and Olufunmilayo I. Olopade1

The first mutation that disrupts BRCA2 mRNA by including a novel, cryptic exon is reported in this issue. The mutation lies deep within an intron and would not have been detected by conventional screening methods. In the future, more mutations may be discovered by direct mRNA analysis. Clin Cancer Res; 18(18): 4865–7. ©2012 AACR.

In this issue of Clinical Cancer Research, Anczuków and colleagues report the first deep intronic BRCA2 mutation resulting in cryptic exon inclusion, the first such mutation to be found in either the BRCA1 or BRCA2 breast/ovarian tumor suppressor genes (1). Germline mutations in BRCA1 or BRCA2 (collectively BRCA1/2) predict generally high (but highly variable) lifetime risks of breast or ovarian cancer (2, 3). Given a positive BRCA1/2 mutation test result, presymptomatic interventions include intensive surveillance or prophylactic surgeries to remove healthy breasts and ovaries. Patients who already have breast or ovarian cancer, along with significant personal or family history of familial breast/ovarian cancer, may seek BRCA1/2 mutation testing, as positive results may inform treatment options and provide potentially life-saving information to family members (4). Thus, genetic testing for germline BRCA1/2 mutations is an important component of comprehensive breast/ovarian cancer care, and biologically informed mutation detection methods are critical to this effort. Conventional genetic testing involves germline sequence analysis of BRCA1/2 exons and flanking intron–exon boundaries, along with molecular assays for some large-scale BRCA1/2 genomic rearrangements. Anczuków and colleagues (1) provide an example of a functionally oriented mutation detection assay that revealed a mutation that would have been missed by more conventional methods. Specifically, they identified a BRCA2 splicing defect caused by inclusion of a cryptic exon, resulting from a deep intronic base change. This work illustrates a practical complement to older mutation detection methods, yet it is only used routinely by a handful of laboratories.

The authors found the cryptic exon by conducting reverse-transcriptase PCR (RT-PCR) analysis of BRCA2 transcripts from patients in the Rhone-Alpes area who were referred for genetic testing because of family history of breast/ovarian cancer. After observing the 95 nucleotide sequence inserted between exons 12 and 13 in one family, they conducted a sequence analysis of the surrounding intronic DNA and found a single base substitution (c.6937+594T>G) that enhances the predicted strength of a 5′ splice site (Fig. 1). Indeed, minigene experiments confirm this single base change alone can confer exon identity on the otherwise-cryptic 95-base exon. To determine the prevalence of this mutation, the authors screened individuals from over 2,000 breast and/or ovarian cancer families and found it in 8 additional families. Of these, 6 families were examined further, and the mutation was found in all 13 affected individuals tested, showing that the mutation segregated with cancer in these families in strong support for the deleterious nature of the mutation. However, the frequency of the mutation among unaffected family members was not presented and penetrance was not estimated.

The authors further speculate on the interesting idea that the deleterious cryptic exon could be a target for antisense oligonucleotide therapy. Using their minigene system, they show that an oligonucleotide spanning the 5′ untranslated region (UTR) residing in the cryptic exon and restore normal splicing of BRCA2 exons 12 and 13. It will be interesting to see whether such an oligonucleotide will have the same effect in the context of splicing all 27 BRCA2 exons.

Although this particular mutation was seen in only 9 of 2,000 (0.5%) families examined, it is likely that mRNA-based mutation detection methods will identify other previously unidentified deleterious mutations. Will such mutations be significant contributors to breast/ovarian cancer risk? That is difficult to know, but it is worth considering that only 44% of patients predicted to carry a BRCA1 or BRCA2 mutation test positive for recognized mutations in either gene (5). In addition, only 63% of familial breast cancers that map to the BRCA1 locus on chromosome 17 carry detectable mutations in the BRCA1 DNA sequence (6). Collectively, these observations suggest there may be large numbers of mutations in BRCA1 or BRCA2 that are either not detected by conventional sequencing analysis, or are not recognized as deleterious even when they are detected.

There are several types of mutations seen in other disease-associated genes that would also be potentially missed by current screening strategies, and these have never been systematically sought in BRCA1 or BRCA2. These include promoter mutations, mutations in 5′ and 3′ untranslated...
base change promotes efficient inclusion of the cryptic splice site prediction algorithms to determine why a single cancer risk. In the current article, the authors make use of B, T included as a high-frequency exon among cryptic exon.

Figure 1. A, a sequence within intron 12 of BRCA2 is somewhat exon-like but does not have a sufficiently strong 5' exon donor site to be efficiently included as a high-frequency exon among BRCA2 splice variants. B, T>G transversion generates a much stronger 5' exon donor site consensus sequence, resulting in high-frequency inclusion of the cryptic exon.

mRNA that could affect message stability and/or processing, deep intronic mutations that promote exon-skipping, spurious "exonization" of genomic repeat elements, or other types of splicing defect (7).

Importantly, Anczukow and colleagues show, using isoform-specific RT-PCR, that the cryptic exon inclusion associated with the intronic base change can also be detected at low levels among wild-type BRCA2 mRNA products. Because the relative abundance of mutation-associated alternate splice variants may not be "all or none," it is critical to characterize the penetrance of the mutation. Events resulting in increased levels of different splice variants will not necessarily always be phenotypically deleterious.

With the wealth of genomic sequence data now available, it is worth asking whether this deep intronic variant would have been recognized as potentially deleterious had it been seen during sequence analysis. Certainly bioinformatics will play an increasingly important role in assessing the true contribution of BRCA1 and BRCA2 mutations and for that matter other yet uncharacterized genes to breast cancer risk. Genome-wide association studies (GWAS) have successfully contributed to provide large numbers of intronic single-nucleotide polymorphisms (SNPs) with significant associations to diseases or traits. Analysis of high-throughput sequencing data (10) has advanced the identification of SNPs that primarily affect alternative splicing. However, the molecular mechanisms by which intronic SNPs affect alternative splicing and increase risk of disease remain largely unknown. Thus, there is a great need to initiate a new era of research that investigates how intronic SNPs affect alternative splicing, including activation of cryptic exons, in clinically relevant genes such as those described in this report. Bioinformatics tools developed for splice site predictions (11) have successfully contributed to identification of novel cryptic exons in dystrophy research (12).

Although bioinformatics may make increasingly powerful predictions about splicing defects in the future, such predictions will always require molecular testing. Also, as the number of rare mutant alleles of BRCA1 and BRCA2 and other cancer susceptibility genes grows, the need for creative methods for assessing the mutation status in individual families and their clinical significance becomes more pressing.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interests were disclosed.

**Grant Support**

This work was supported by funds from the Ralph and Marion Falk Medical Research Trust and the NIH/NCI SPORE in Breast Cancer P50 CA125183 (O.I. Olopade).

**Authors’ Contributions**

Conception and design: J.D. Fackenthal, O.I. Olopade

Development of methodology: O.I. Olopade

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): J.D. Fackenthal

Writing, review, and/or revision of the manuscript: J.D. Fackenthal, Y. Lee, O.I. Olopade

Study supervision: O.I. Olopade

Received July 25, 2012; accepted July 31, 2012; published OnlineFirst August 6, 2012.

**References**

Hidden Dangers: A Cryptic Exon Disrupts BRCA2 mRNA

James D. Fackenthal, Younghee Lee and Olufunmilayo I. Olopade


Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-12-2090

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2012/09/12/1078-0432.CCR-12-2090.DC1

Cited articles
This article cites 12 articles, 1 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/18/18/4865.full.html#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.